(CRL) Charles River Laboratories - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 7.721m USD | Total Return: 48.9% in 12m
Avg Turnover: 135M
EPS Trend: -57.6%
Qual. Beats: 0
Rev. Trend: -91.0%
Qual. Beats: 1
Warnings
Choppy Below Avwap Earnings
Tailwinds
Idiosyncratic Leader
Charles River Laboratories International, Inc. (CRL) is a global provider of drug discovery, non-clinical development, and safety testing services. The company operates through three primary segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Its business model relies on the outsourcing trend within the pharmaceutical and biotechnology industries, where firms delegate specialized laboratory work to reduce fixed costs and accelerate development timelines.
The company maintains a significant market share in the production of research models, specifically purpose-bred rodents used in pre-clinical trials. Beyond animal models, CRL provides essential services in toxicology, pathology, and cell therapy production, as well as rapid quality control testing for sterile pharmaceuticals. This sector is characterized by high barriers to entry due to stringent regulatory requirements and the specialized infrastructure needed for vivarium management and biologic testing.
CRL actively pursues strategic alliances with research institutions and medical centers to advance technologies such as Antibody-Drug Conjugates (ADCs) and cancer immunotherapies. For a deeper analysis of these market dynamics, you may find it useful to review the quantitative data on ValueRay. Headquartered in Wilmington, Massachusetts, the firm serves as a critical link in the global drug development supply chain, supporting the transition of molecules from early-stage discovery to clinical readiness.
- Biotechnology funding levels and R&D spending cycles dictate preclinical service demand
- Global research model supply chain stability impacts Research Models and Services margins
- Expansion into cell and gene therapy manufacturing drives long-term revenue diversification
- Regulatory scrutiny of non-human primate sourcing increases operational costs and legal risks
- Outsourcing trends in pharmaceutical safety assessment influence Discovery and Safety segment growth
| Net Income: -184.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.37 > 1.0 |
| NWC/Revenue: 9.81% < 20% (prev 11.32%; Δ -1.51% < -1%) |
| CFO/TA 0.08 > 3% & CFO 607.0m > Net Income -184.7m |
| Net Debt (3.26b) to EBITDA (804.2m): 4.05 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.0m) vs 12m ago -3.74% < -2% |
| Gross Margin: 31.86% > 18% (prev 0.32%; Δ 3.15k% > 0.5%) |
| Asset Turnover: 52.60% > 50% (prev 53.05%; Δ -0.45% > 0%) |
| Interest Coverage Ratio: 4.29 > 6 (EBITDA TTM 804.2m / Interest Expense TTM 105.9m) |
| A: 0.05 (Total Current Assets 1.49b - Total Current Liabilities 1.09b) / Total Assets 7.73b |
| B: 0.18 (Retained Earnings 1.37b / Total Assets 7.73b) |
| C: 0.06 (EBIT TTM 454.1m / Avg Total Assets 7.66b) |
| D: 0.25 (Book Value of Equity 1.18b / Total Liabilities 4.74b) |
| Altman-Z'' = 1.58 = BB |
| DSRI: 0.92 (Receivables 700.3m/756.6m, Revenue 4.03b/4.02b) |
| GMI: 1.02 (GM 31.86% / 32.43%) |
| AQI: 1.06 (AQ_t 0.57 / AQ_t-1 0.54) |
| SGI: 1.00 (Revenue 4.03b / 4.02b) |
| TATA: -0.10 (NI -184.7m - CFO 607.0m) / TA 7.73b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 156.73 with a total of 1,024,010 shares traded.
Over the past week, the price has changed by -3.13%,
over one month by +18.85%,
over three months by +35.23% and
over the past year by +48.91%.
Charles River Laboratories has received a consensus analysts rating of 3.32. Therefore, it is recommended to hold CRL.
- StrongBuy: 4
- Buy: 0
- Hold: 14
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 208.8 | 33.2% |
P/E Forward = 14.4092
P/S = 1.9174
P/B = 2.6258
P/EG = 0.1222
Revenue TTM = 4.03b USD
EBIT TTM = 454.1m USD
EBITDA TTM = 804.2m USD
Long Term Debt = 2.66b USD (from longTermDebt, last quarter)
Short Term Debt = 61.1m USD (from shortTermDebt, last fiscal year)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter) + Leases 393.1m
Net Debt = 3.26b USD (calculated: Debt 3.45b - CCE 191.8m)
Enterprise Value = 11.0b USD (7.72b + Debt 3.45b - CCE 191.8m)
Interest Coverage Ratio = 4.29 (Ebit TTM 454.1m / Interest Expense TTM 105.9m)
EV/FCF = 28.06x (Enterprise Value 11.0b / FCF TTM 391.3m)
FCF Yield = 3.56% (FCF TTM 391.3m / Enterprise Value 11.0b)
FCF Margin = 9.72% (FCF TTM 391.3m / Revenue TTM 4.03b)
Net Margin = -4.59% (Net Income TTM -184.7m / Revenue TTM 4.03b)
Gross Margin = 31.86% ((Revenue TTM 4.03b - Cost of Revenue TTM 2.74b) / Revenue TTM)
Gross Margin QoQ = 28.05% (prev 30.96%)
Tobins Q-Ratio = 1.42 (Enterprise Value 11.0b / Total Assets 7.73b)
Interest Expense / Debt = 3.07% (Interest Expense 105.9m / Debt 3.45b)
Taxrate = 21.0% (US default 21%)
NOPAT = 358.7m (EBIT 454.1m * (1 - 21.00%))
Current Ratio = 1.36 (Total Current Assets 1.49b / Total Current Liabilities 1.09b)
Debt / Equity = 1.17 (Debt 3.45b / totalStockholderEquity, last quarter 2.94b)
Debt / EBITDA = 4.05 (Net Debt 3.26b / EBITDA 804.2m)
Debt / FCF = 8.33 (Net Debt 3.26b / FCF TTM 391.3m)
Total Stockholder Equity = 3.22b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.41% (Net Income -184.7m / Total Assets 7.73b)
RoE = -5.74% (Net Income TTM -184.7m / Total Stockholder Equity 3.22b)
RoCE = 7.72% (EBIT 454.1m / Capital Employed (Equity 3.22b + L.T.Debt 2.66b))
RoIC = 5.44% (NOPAT 358.7m / Invested Capital 6.60b)
WACC = 8.79% (E(7.72b)/V(11.2b) * Re(11.64%) + D(3.45b)/V(11.2b) * Rd(3.07%) * (1-Tc(0.21)))
Discount Rate = 11.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -2.34%
[DCF] Terminal Value 71.45% ; FCFF base≈460.1m ; Y1≈403.5m ; Y5≈326.0m
[DCF] Fair Price = 33.57 (EV 4.87b - Net Debt 3.26b = Equity 1.62b / Shares 48.2m; r=8.79% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -57.64 | EPS CAGR: -2.22% | SUE: 0.73 | # QB: 0
Revenue Correlation: -90.97 | Revenue CAGR: -1.62% | SUE: 1.14 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.73 | Chg30d=+1.51% | Revisions=+9% | Analysts=12
EPS next Quarter (2026-09-30): EPS=3.05 | Chg30d=-2.56% | Revisions=-27% | Analysts=12
EPS current Year (2026-12-31): EPS=11.09 | Chg30d=+0.21% | Revisions=+38% | GrowthEPS=+7.9% | GrowthRev=-4.3%
EPS next Year (2027-12-31): EPS=12.31 | Chg30d=-0.83% | Revisions=+17% | GrowthEPS=+11.0% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: +38%